Virology
We strive to break new ground in comprehensive care for patients living with the hepatitis C virus.
The HCV Landscape
The hepatitis C virus (HCV) was once a hard to treat, chronic disease, but the availability of new treatments such as direct-acting antivirals (DAAs), which can virologically combat the disease in specific genotypes, are impacting the way we care for chronic HCV patients.
Our HCV Pipeline Program
Our goal is to provide a treatment option for as many chronic HCV patients as possible, from first-generation treatment failures to special populations. We are currently examining treatments for a pan-genotypic (genotypes 1-6), short-course treatment that addresses emerging treatment challenges for patients living with chronic HCV.
160 million
people worldwide are affected by chronic hepatitis C *
*Source: Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2):107-15
3 to 4 million
new cases of hepatitis C infection each year*
*Source: IFPMA 2014. Towards a sustainable, intersectoral approach to viral hepatitis
Our HCV Commitment
We are committed to working with governments, patient advocates, public health experts and other leading HCV stakeholders to help address unmet needs across the world for patients living with chronic HCV.